<DOC>
	<DOCNO>NCT02931071</DOCNO>
	<brief_summary>Fanconi anemia ( FA ) congenital disease characterize bone marrow failure increase incidence malignant tumor . The Project pursue optimization collection hematopoietic progenitor cell later use another clinical trial entitle `` Clinical Trial Phase I/II evaluate safety efficacy infusion autologous CD34+ cell mobilize mozobil filgrastim , transduce lentiviral vector carry FANCA gene ( Orphan Drug ) patient Fanconi Anemia Subtype A `` . The objective study , therefore , assess safety efficacy CD34+ cell mobilization mozobil filgrastim , postulate efficient collection CD34+ cell FA patient .</brief_summary>
	<brief_title>Clinical Phase II Trial Evaluate CD34+ Cells Mobilization Collection Patients With Fanconi Anemia Subsequent Transduction With Lentiviral Vector Carring FANCA Gene . FANCOSTEM-1</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Fanconi Anemia</mesh_term>
	<mesh_term>Fanconi Syndrome</mesh_term>
	<mesh_term>JM 3100</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Male female &gt; 1 year diagnose Fanconi 's anemia confirm instability chromosomal test diepoxybutane mitomycin C At least one follow parameter must high value : Hemoglobin:8,0 g/dL ; neutrophil : 750/mm3 ; platelet : 30.000/mm3 Lansky index &gt; 60 % . Left ventricular ejection fraction &gt; 50 % . To grant informed consent agreement current law norm Women childbearing age must obtain negative result pregnancy test serum urine visit selection accept use suitable contraceptive method since least 14 day prior first dose mobilize treatment 14 day follow last Evidence myelodysplastic syndrome leukemia , cytogenetic abnormality predict syndromes bone marrow aspiration . Cytogenetic analysis perform 2 month start study accept Patients active infection process underlay severe medical process Severe Functional alteration organ ( hepatic , renal , respiratory ) ( ? 3 ) , accord National Cancer Institute ( NCI CTCAE v3 ) criterion Haematopoietic transplant Any disease concomitant process compatible study per investigator opinion Patients elegible psicosocial evaluation Patients receive transfusional support last 3 month . Pregnant breastfeeding woman</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>